Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
An open-label, Phase II clinical study to evaluate the efficacy and safety of lanreotide
autogel 90mg every 4 weeks in the treatment of symptomatic polycystic liver disease,
including a dose escalation at month 6 to lanreotide autogel 120mg for non responders.